Introduction
============

Lung cancer is the most common cause of cancer-related mortality worldwide [@B1]. The overall 5-year survival rate of lung cancer is dismal as cancer cases are usually diagnosed at later stages [@B2]. Lung cancer exhibits the following two predominant pathological types: non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Non-small cell lung cancer accounts for approximately 85% of all lung cancer cases, and adenocarcinoma is the most common subtype of lung cancer. Despite advances in therapeutic methods, the survival rates of lung cancer remain low. Therefore, identification of novel molecular abnormalities that contribute to lung cancer pathogenesis, patient outcome and therapeutic targets, is urgently needed to improve individualized treatment.

The *COPS3* (constitutive photomorphogenic homolog subunit 3 of COP9) gene is located on chromosome 17p11.2-12 in humans and encodes the third subunit of the eight-subunit COP9 signalosome (CSN) complex, which was initially identified as a negative regulator of constitutive photomorphogenesis in Arabidopsis thaliana [@B3]. The COP9 signalosome is an evolutionarily conserved protein complex that exhibits protein kinase and deneddylase activities. The protein encoded by *COPS3* acts as a docking site for the signalosome, thereby mediating the phosphorylation of a wide variety of important regulators involved in signal transduction, including I kappa-B alpha, p105, ITPK1, IRF8/ICSBP, c-Jun, p53, and p27 [@B4].

*COPS3* plays an important role in both the tumorigenesis and progression of osteosarcoma and hepatocellular carcinoma [@B5]-[@B7]. The overexpression of *COPS3* has been found to be correlated with proliferation, metastasis and apoptosis [@B7]-[@B9]. In addition, clinical data indicate that the overexpression of *COPS3* significantly correlates with poor outcome in osteosarcoma patients [@B10]. Through constructing a transcriptome map of human lung tissue, Zhou and colleagues have discovered the amplification of 17p11 in lung cancer [@B11], suggesting that *COPS3* might contribute to the development of lung cancer.

In a previous *cell*study, we have demonstrated that *COPS3* is highly expressed in lung adenocarcinoma cell lines [@B11]. Knockdown of *COPS3* significantly inhibits tumor cell proliferation in this *in vitro* model. However, the specific role of *COPS3 in vivo* remains to be defined. In this extended study, we focused on the role of *COPS3* in an *in vivo* tumor xenograft model. After RNA interference-mediated knockdown of COPS3, we examined the development of lung cancer in nude mice. We further evaluated the correlation between *COPS3* expression and clinicopathological features in a cohort of cancer patients.

Materials and Methods
=====================

Collection of lung cancer samples
---------------------------------

A total of 120 formalin-fixed and paraffin-embedded human lung carcinoma samples were collected for *COPS3*expression analysis, including 37 cases of squamous carcinoma, 40 cases of adenocarcinoma, and 43 cases of small cell lung carcinoma. All cases were histopathologically and clinically diagnosed at the First Hospital of Jilin University from 2010 to 2015. All samples were reviewed retrospectively and diagnosed according to the 2015 World Health Organization (WHO) Classification of Tumors of the Lung, Pleura, Thymus and Heart [@B12]. The study protocol was approved by the Human Medical Ethical Review Committee of the hospital at Jilin University. Informed consent was obtained from each cancer patient at the beginning of the study.

Immunohistochemistry of COPS3 expression
----------------------------------------

Paraffin-embedded human lung cancer tissues were fixed in freshly prepared 10% neutral buffered formalin, embedded in paraffin wax, and cut into 4-μm sections. Tissues at least 3 cm away from the cancer mass were collected as the adjacent "normal lung tissue". After being baked at 65°C for 1 hour, the sections were deparaffinized and rehydrated. Endogenous peroxidase activity was blocked by 3% hydrogen peroxide for 10 minutes at room temperature. After blocking with 5% bovine serum albumin (BSA), the sections were incubated with anti-*COPS3* antibody (2.5 µg/ml) at 37°C for 2 hours, and this was followed by incubation with a second antibody from the MaxVisionTM kit (Maxim, China) for 15 minutes at room temperature. Sections were counterstained with hematoxylin.

The immunostaining was scored blindly by two independent skilled pathologists, based on the intensity and localization of staining. The proportion of tumor cells was scored as follows: 0 (no positive tumor cells), 1 (≤10% positive tumor cells), 2(10-50% positive tumor cells), and 3 (≥50% positive tumor cells). The staining intensity was classified according to the following criteria: 0 (negative staining), 1 (weak staining: weak yellow), 2 (moderate staining: yellow-brown), and 3 (strong staining: brown). For semi-quantitative analysis, the final score of each case was calculated as a percentage of positive cells multiplied by staining intensity (IHC score = Σ(intensity×% positive cells). An optimal cutoff value was identified as follows: a final score of ≥4 was defined as the group with high *COPS3* expression, whereas a score of ≤3 was defined as the group with low *COPS3* expression.

Cell culture study
------------------

The lung adenocarcinoma cell line (A549) and the human embryonic kidney cell line (293T) were purchased from American Type Culture Collection (ATCC, VA). The cell lines were maintained in DMEM supplemented with 10% FBS at 37°C in a humidified incubator with constant air flow of 5% CO2.

Lentivirus packaging and transfection of A549 cells
---------------------------------------------------

The short hairpin RNA (shRNA) nucleotide sequences were inserted into the pFH1UGW-GFP vector (Hollybio, Shanghai, China) and were confirmed by DNA sequencing. A random shRNA sequence (shCTRL) was served as a control (Hollybio, Shanghai, China). Lentiviruses were generated via the transfection of 293T cells at 70-80% confluence. Two hours before transfection, the FBS-containing medium was removed and replaced with 200 µl of Opti-MEM containing 20 µg pFH1UGW-GFP-sh*COPS3* or -shCTRL, 15 µg pCMV vector and 10 µg pVSVG plasmid prepared with 15 µl of Lipofectamine 2000. After incubation for 8 h, the medium was replaced with 10 ml DMEM supplemented with 10% FBS. The supernatant was collected after 48 hours of transfection, and lentiviral particles were harvested by centrifugation (4,000 g) at 4°C for 10 min. The collected viral particles were filtered through a 45-μm filter, and the filtrate was centrifuged (4, 000 g at 4°C) for 15 min to collect the concentrated lentiviruses.

A549 cells were seeded on a 6-well plate at a concentration of 5×10^4^ cells/well. After 24 hours of incubation, the culture medium was replaced with Opti-MEM medium containing the appropriate amount of lentiviruses. Cells were transfected with the *COPS3* shRNA-expressing lentiviruses in the sh-*COPS3* group and the control shRNA-expressing lentiviruses in the sh-CTRL group, respectively. Twenty-four hours after transfection, the medium was replaced with fresh medium, and the cells were further incubated for an additional 72 hours. Successful transfection was assessed by fluorescence microscope to examine the expression of green fluorescent protein.

Real-time PCR analysis
----------------------

RNA was extracted from virally infected lung cancer cells on day 5. Cells were lysed using TRIzol reagent (Invitrogen, CA), and total RNA was extracted from the lysate following the manufacturer\'s protocol. cDNA was synthesized from the extracted RNA using a Promega M-MLV cDNA synthesis kit, according to the manufacturer\'s instruction. Real time PCR analysis was performed to evaluate *COPS3* mRNA expression in sh-*COPS3* and sh-CTRL infected cells. β-ACTIN was used as the internal reference control for PCR. Relative gene expression levels were calculated using 2^-△△CT^ analysis, as previously described [@B13], [@B14] .

Western blotting
----------------

The expression of *COPS3* protein, cyclin B1, cyclin D1, CDK4 and CDK2 was detected by western blotting. Briefly, cells were infected with sh-*COPS3* and sh-CTRL for 5 days and were lysed with lysis buffer (0.15 M NaCl, 5 mM EDTA, pH 8, 10 mM Tris-Cl, PH 7.5, 1% Triton-X100). Protein contents were measured using the Lowry method. The protein concentration of each sample was adjusted to 2 µg/µl, and 20-µg protein samples were electrophoresed on 10% SDS-PAGE and transferred onto polyvinylidenedifluoride membranes. Protein expression was detected with the indicated antibodies. Band densities were quantified with the Image J program[@B15].

Cell cycle analysis
-------------------

Cell cycle was analyzed by flow cytometric analysis after popidium iodide (PI) staining [@B16], [@B17]. Infected cells were seeded onto 6-well plates at a concentration of 1×10^6^/well and incubated for 24 hours. Cells were collected by trypsinization, washed with ice cold PBS, and then fixed by resuspension in 0.7 ml of 70% ethanol for 30 min at 4°C. The ethanol was removed by centrifugation and a PI solution containing 10 µg/ml of DNase-free RNase A was added to stain the cells for 30 min. Cell suspensions were filtered through a 50-µm nylon mesh and then analyzed with flow cytometry (FAS Calibur, BD Biosciences, CA).

Tumorigenesis in nude mice
--------------------------

The role of *COPS3* in lung cancer tumorigenesis was examined in BALB/c nude mice (8-12 weeks old, 22±3 g). Animals were purchased from the Experimental Animal Center of College of Basic Medical Sciences, Jilin University and were randomized into two groups (20 mice in each group). A549 cell suspensions (0.25 ml) infected with sh-*COPS3* or sh-CTRL (5×10^6^ cells/ mouse) were subcutaneously injected into the armpits or the backs of the mice. Tumor sizes were recorded on days 10, 17, 24 and 31 as maximum diameter (A, mm) and vertical short diameter (B, mm). The tumor volumes were calculated using the formula V (mm^3^) = ½(AxB^2^) as previously described [@B18]. After 31 days of observation, the mice were sacrificed, and the xenograft tumors were removed and weighed for analysis. The animal protocol was approved by the Animal Care and Use Committee of the Fist Affiliated Hospital in Jilin University.

Statistical analysis
--------------------

All data were statistically analyzed using the SPSS 16.0 software package. Correlation analysis between *COPS3* expression and clinicopathological data was performed with Fisher\'s exact probability test. After variables were confirmed to be related to *COPS3* levels, a Chi-Square test among the three groups was performed. The correlation between Ki-67 indices and *COPS3* scores was calculated by Spearman\'s rank correlation test. P values \<0.05 were considered to be statistically significant.

Results
=======

COPS3 expression is correlated with clinicopathological characteristics in lung cancer patients
-----------------------------------------------------------------------------------------------

The clinicopathological characteristics and *COPS3* expression levels in patients with lung cancer are summarized in **Table [1](#T1){ref-type="table"}**. We found that the expression level of *COPS3* protein was significantly associated with the histological type (P =0.001), with higher COPS3 expression in small cell carcinoma (86%) and squamous cell carcinoma (86.5%) than that in adenocarcinoma (52.5%). We found that COPS3 expression was also significantly higher in the low-differentiation tumors (86%) than that in the high-differentiation tumors (50%) (P =0.012). Interestingly, COPS3 was also positively associated with Ki-67 index in lung cancer patients (P =0.001).

Overall, COPS3 protein was more abundant in squamous carcinoma and small cell carcinoma than that in adenocarcinoma. However, no significant association of *COPS3* expression was found with age, tumor size, N classification, status of distant metastases (M classification), or clinical staging in 120 cancer cases.

COPS3 is upregulated in lung cancer tissues
-------------------------------------------

**Figure [1](#F1){ref-type="fig"}** shows the representative images of the overexpressed COPS3 in lung cancer tissues. We found that *COPS3* was overexpressed in cancer tissues (red arrow) compared with adjacent normal lung tissues (right panels). In agreement with the data in **Table [1](#T1){ref-type="table"}**, *COPS3* expression was significantly higher in small cell lung carcinoma and squamous carcinomas than that in adenocarcinoma.

COPS3 knockdown inhibits tumor growth in nude mice
--------------------------------------------------

In a previous *in vitro* study, we reported that *COPS3* promoted cell proliferation in two lung cancer cell lines, including A549 (adenocarcinoma) and 95D (metastatic lung cancer) [@B11]. In this extended study, we focused on the role of COPS3 in tumorigenesis in nude mice. For this, adenocarcinoma A549 cells were used to establish the xenograft tumor model.

In this *in vivo* study, we found that tumor volume was remarkably smaller in the sh-*COPS3* group than that in the sh-CTRL control group (**Figs.[2](#F2){ref-type="fig"}A** and **2B**, P\<0.05). Similarly, the mice in the sh-*COPS3* group showed a significant reduction in tumor weight, as compared with those in the sh-CTRL controls (**Fig.[2](#F2){ref-type="fig"}C**, P\<0.05).

Knockdown of COPS3 expression induces cell-cycle arrest at G0/G1 phase
----------------------------------------------------------------------

To examine the mechanism underlying the role of *COPS3* in tumorigenesis, we used flow cytometry (FACS) to repeat cell cycle analysis as previously reported in these cells [@B11]. We found that lung cancer cells treated with sh-*COPS3* were predominantly arrested at G0/G1 phase (**Fig. [3](#F3){ref-type="fig"}A**). Cell cycle quantification showed that compared with the sh-CTRL control, knockdown of *COPS3* with shRNA significantly blocked A549 lung cancer cells at G0/G1 phase (**Fig. [3](#F3){ref-type="fig"}B**, P\<0.01).

COPS3 knockdown alters expression of the cell-cycle pathway proteins
--------------------------------------------------------------------

To further investigate the underlying molecular mechanisms, several cell-cycle associated factors were quantified by Western blotting. In the sh-COPS3-infected A549 cells, the expression of P21 was significantly upregulated (**Figs.[4](#F4){ref-type="fig"}A-[4](#F4){ref-type="fig"}F**, P\<0.05). In contrast, the knockdown of *COPS3* dramatically reduced the expression of cyclin B1 and CDK4 (P\<0.05). However, knockdown of *COPS3* did not affect the expression of other two cell-cycle genes cyclin D1 and CDK2 in A549 cells.

Discussion
==========

*COPS3* has been reported to participate in the progression of several tumors [@B5]-[@B7], [@B19]. However, the role of *COPS3* in human lung cancer remains to be defined. In this study, we examined the expression of *COPS3* in a total of 120 lung cancer patients. By comparison with adjacent lung tissues, we demonstrate that *COPS3* is highly expressed in lung cancer tissues, particularly in small cell carcinoma and squamous cell carcinoma. The upregulation of *COPS3* was associated with poor differentiation. Therefore, our data suggest that *COPS3* might be another molecular marker in lung cancer, particularly small cell carcinoma and squamous cell carcinomas.

Previously, we have shown that *COPS3* plays an important role in stimulating cell proliferation in lung cancer cells [@B19]. In this cohort study, we also found that the level of *COPS3* expression was positively correlated with Ki-67 index in lung cancer patients. The Ki-67 protein is a well-known cellular marker for proliferation [@B20]. Thus, *COPS3* might be an important regulator in cellular proliferation. To further demonstrate the role of *COPS3* in proliferation *in vivo*, we used a nude mouse model that was xenografted with A549 cells in which *COPS3* was knocked down by shRNA. Our results show that knockdown of *COPS3* expression dramatically reduces both tumor size and weight. Our *in vivo* tumor study further confirms the hypothesis that *COPS3* promotes tumorigenesis by regulating proliferation. Most published reports have focused on *COPS3*-mediated mechanisms of metastasis and apoptosis [@B7], [@B9]. However, we did not find a correlation between *COPS3* and tumor metastasis in our model.

The cell cycle is governed by two specific checkpoints: G1-S and G2-M phases. Cell cycle progression is regulated by Cyclins and Cyclin-dependent kinases (CDKs) [@B21]. Transition from G1 to S phase requires the activation of Cyclin D/CDK4 and Cyclin E/CDK2 complexes [@B22], [@B23]. CDK4 is often overexpressed in lung cancer, particularly in adenocarcinoma, and is a significant predictor of poor prognosis for lung cancer patients [@B24]. In this study, A549 cells treated with sh-*COPS3* were predominantly arrested at G0/G1 phase. By examining the CDKs, we found that the sh-*COPS3* treatment induced significant downregulation of CDK4 (**Fig. [4](#F4){ref-type="fig"}**), with simultaneous G0/G1 arrest in the treated cells. However, CDK2 was not significantly affected by sh-*COPS3* knockdown. Our data therefore suggest that the G0/G1 cell cycle arrest induced by *COPS3* knockdown was primarily mediated through the down-regulation of CDK4.

As a protein that suppresses Cyclin E/A-CDK2 activity, P21 inhibits the activities of the Cyclin E/CDK2 and CyclinA/CDK2 complexes at G1/S and G2/M phase checkpoints [@B25], [@B26]. The COP9 signalosome has also been reported to control E3 ubiquitin (Ub) ligases, through which CSN controls the degradation of a wide variety of proteins, such as P53. Consequently, the levels of target proteins of P53, such as P21, are reduced. In this study, we showed that knockdown of *COPS3* also significantly upregulates the expression of P21. Thus, the upregulation of P21 may also contribute to cell cycle arrest at G0/G1 phase.

During G2 phase, Cyclin A/CDK2 and Cyclin B1/CDK1 complexes regulate M phase entry [@B21]. Using flow cytometry, we found that the sh-*COPS3*-treated A549 cells, compared with the sh-CTRL-treated A549 cells, showed a decreased proportion of cells in G2/M phase. By assessing G2 phase regulators, we found that Cyclin B1 was significantly downregulated in the sh-*COPS3*-treated A549 cells, thus suggesting that the down-regulation of Cyclin B1 might be related to the reduced proportion of sh-*COPS3* A549 cells in G2/M phase.

In summary, this study suggests that *COPS3* might be a novel molecular marker in lung cancer, for its high expression in lung cancer. *COPS3* promotes the proliferation of lung cancer cells, increasing S-phase cells by regulating cell cycle-associated proteins. These data suggest an important role of *COPS3*in regulating cell cycle progression of lung cancer cells. Further studies are required to confirm the molecular regulatory mechanism, clinical significance and prognostic value of *COPS3* in lung cancer.
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![**Representative images of COPS3 immunohistochemical staining in lung cancer tissues and adjacent normal lung tissues.**A-C. H&E and immunohistochemical (IHC) staining of adenocarcinoma and adjacent normal lung tissues; D-F: H&E and immunohistochemical (IHC) staining of squamous carcinoma and adjacent normal lung tissues; G-I: H&E and immunohistochemical (IHC) staining of SCLC and adjacent normal lung tissues. The images of H&E staining were taken at 40× magnification, and the images of IHC at 200× magnification. Tissues at least 3 cm away from the cancer mass were collected as adjacent "normal lung tissue". Note that the COPS3 immunostaining was more immunoreactive in cancer tissues than that in adjacent normal lung tissues.](jcav08p1129g001){#F1}

![***COPS3* shRNA knockdown inhibits tumor growth in nude mice. A.**Representative images of xenograft tumors in nude mice treated with sh-*COPS3* and sh-CTRL. Red boxes indicate the location and size of the tumors. **B.**Reduction of tumor growth in nude mice treated with sh-*COPS3*. \*P\<0.05 compared with the sh-CRTL control. **C.**Tumor weights in the nude mice treated with sh-*COPS3*. \*P\<0.05 compared with the sh-CRTL control.](jcav08p1129g002){#F2}

![**Down-regulation of *COPS3* induces cell cycle arrest at G0/G1 phase. A.** The cell cycle distribution of A549 cells as assessed by flow cytometry. **B.** G0/G1 phase blockage in sh-*COPS3* A549 cells. Values were presented as the mean values ±standard deviation of three independent experiments. \*\* P\<0.01 compared with the sh-CRTL control group.](jcav08p1129g003){#F3}

![**Activation of cell cycle related proteins by *COPS3* knockdown. A.** Activation of cell cycle related proteins. Expression of Cyclin D1, CDK4, Cyclin B1, CDK2 and P21 was detected by Western blotting. GADPH protein was used as an internal control. **B.** Quantification of cell cycle related proteins expression. \* P\<0.05 compared with the sh-CTRL A549 cells.](jcav08p1129g004){#F4}

###### 

Correlation between the clinicopathologic characteristics and expression of COPS3 protein in lung cancer

  Characteristics                                      n            COPS3 (%)    P             
  ----------------------------- ---------------------- ------------ ------------ ------------- -------
  Gender                                                                                       
                                Male                   84           61 (72.6%)   23 (27.4%)    
                                Female                 36           29 (80.6%)   7 (19.4%)     0.491
  Age(y)                        ≥65                    27           18 (66.7%)   9 (33.3%)     
                                \<65                   93           72 (77.4%)   21 (22.6%)    0.313
  Histological classification                                                                  
                                Small cell carcinoma   43           37 (86.0%)   6 (14.0%)     
  adenocarcinoma                40                     21 (52.5%)   19 (47.5%)                 
  squamous cell carcinoma       37                     32 (86.5%)   5 (13.5%)    0.001         
  Tumor size (cm)                                                                              
                                ≤3                     59           44 (74.6%)   15 (25.4%)    
  4-7                           57                     43 (75.4%)   14 (24.6%)                 
  \>7                           4                      3 (75%)      1 (25%)      1.000         
  Differentiation                                                                              
                                Low                    57           49 (86.0%)   8 (14.0%)     
  Moderate                      54                     36 (66.7%)   18 (33.3%)                 
  High                          8                      4 (50.0%)    4 (50.0%)    0.012         
  N classification                                                                             
                                N0                     68           50 (73.5%)   18 (26.5%)    
  N1                            32                     26 (81.2%)   6 (18.8%)                  
  N2                            19                     14 (73.7%)   5 (26.3%)    0.762         
  Distant metastasis                                                                           
                                M0                     114          85 (74.6%)   29 (25.4%)    
  M1                            2                      2 (100.0%)   0 (0.0%)     1.000         
  Ki-67 index                                                                                  
                                \<50%                  52           31 (59.6%)   21 (40.4%)    
  ≥50%                          68                     59 (86.8%)   9 (13.2%)    0.001         
  Clinical stage                                                                               
                                Ⅰ                      56           42 (75.0%)   14 (25. 0%)   
  Ⅱ                             43                     34 (79.1%)   9 (20.9%)                  
  Ⅲ                             18                     12 (66.7%)   6 (33.3%)                  
  Ⅳ                             2                      2 (100.0%)   0 (0.0%)     0.708         
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